Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication
Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Although it is commonly accepted that antiviral therapy should be commenced before or during
hepatocellular carcinoma (HCC) treatment if the patients have high viral loads and elevated
ALT or total bilirubin values with signs of cirrhosis, the dilemma exists when HBV DNA and
liver function (such as ALT, AST, TBIL) remains low level. Whether antiviral therapy make
sense or not in these patients with no signs of hepatitis or high viral replication remains
unclear, especially for the relatively advanced stage HCC patients receiving TACE. Thus, the
investigators carried out this prospective control study to compare the survivals for
patients after TACE between with or without antiviral therapy.